TNF and systemic-onset juvenile idiopathic arthritis: In the pre-biologic era, CS have been the sole effective treatment option for many years, and the mainstay of therapy in most patients with sJIA, while cDMARDs and some newer alternatives such as anti-tumor necrosis factor-α agents had provided unsatisfactory results (Russo and Katsicas, 2009; Stoll and Cron, 2014).